Roche Files CTA for Third Genmab Antibody Summary: Genmab's Partner Roche has Filed a CTA With the British MHRA for a
COPENHAGEN, October 2 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that its partner Roche has filed a Clinical Trial Application (CTA) with the British Medicines and Healthcare products Regulatory Agency (MHRA) for a Genmab antibody developed under the companies' collaboration. Genmab will receive a milestone payment from Roche which does not influence Genmab's financial guidance for 2007.
Under the agreement with Roche, Genmab utilizes its broad antibody expertise and development capabilities to create human antibodies to a broad range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products. In certain circumstances, Genmab may obtain rights to develop products based on disease targets identified by Roche. If all goals are reached, the value of the collaboration to Genmab could be USD 100 million, plus royalties.
"We are pleased that the third antibody created by Genmab under our partnership with Roche is entering the clinic and to now have eight products in clinical development," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "Genmab has now achieved the eleventh milestone under the collaboration."
About Genmab A/S Genmab is a leading international biotechnology
company focused on developing fully human antibody therapeutics for unmet
medical needs. Using unique, cutting-edge antibody technology, Genmab's
world class discovery and development teams have created and developed an
extensive pipeline of products for potential treatment of a variety of
diseases including cancer and autoimmune disorders. As Genmab advances
towards a commercial future, we remain committed to our primary goal of
improving the lives of patients who are in urgent need of new treatment
|SOURCE Genmab A/S|
Copyright©2007 PR Newswire.
All rights reserved